Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 4/2020

29.10.2020 | review

Fertility preservation in women with endometrial cancer

verfasst von: MD Helena Bralo, MD Maria Roethlisberger, MD Assoc. Prof. Kazem Nouri

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Fertility preservation should only be offered to patients with endometrial cancer stage Ia grade 1 (G1), who present without myometrial invasion or where the cancer has invaded less than 50% of the myometrium, with no evidence of pathological lymph nodes or no evidence of synchronous or metachronous ovarian tumor. It is estimated that about 22% will achieve successful pregnancy.
Literatur
6.
Zurück zum Zitat Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol. 1984;64:417–20. PubMed Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol. 1984;64:417–20. PubMed
7.
Zurück zum Zitat Soliman PT, Oh JC, Schmeler KM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005;105:575–80. CrossRef Soliman PT, Oh JC, Schmeler KM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005;105:575–80. CrossRef
8.
Zurück zum Zitat Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012;27:1327–31. CrossRef Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012;27:1327–31. CrossRef
9.
Zurück zum Zitat Tran BN, Connell PP, Waggoner S, et al. Characteristics and outcome of endometrial carcinoma patients age 45 years and younger. Am J Clin Oncol. 2000;23:476–80. CrossRef Tran BN, Connell PP, Waggoner S, et al. Characteristics and outcome of endometrial carcinoma patients age 45 years and younger. Am J Clin Oncol. 2000;23:476–80. CrossRef
10.
Zurück zum Zitat Montz FJ, Bristow RE, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002;186:651–7. CrossRef Montz FJ, Bristow RE, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002;186:651–7. CrossRef
11.
Zurück zum Zitat Duska LR, Garrett A, Rueda BR. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001;83:388–93. CrossRef Duska LR, Garrett A, Rueda BR. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001;83:388–93. CrossRef
12.
Zurück zum Zitat Huang SY, Jung SM, Ng KK, et al. Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment. Gynecol Oncol. 2005;97:652–5. CrossRef Huang SY, Jung SM, Ng KK, et al. Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment. Gynecol Oncol. 2005;97:652–5. CrossRef
13.
Zurück zum Zitat National Institute for Health and Clinical Excellence CG44. Heavy menstrual bleeding. 2007. National Institute for Health and Clinical Excellence CG44. Heavy menstrual bleeding. 2007.
14.
Zurück zum Zitat American College of Obstetricians and Gynecologists. Practice bulletin. Diagnosis of abnormal uterine bleeding in reproductive aged women. Obstet Gynecol. 2012;128:1–11. American College of Obstetricians and Gynecologists. Practice bulletin. Diagnosis of abnormal uterine bleeding in reproductive aged women. Obstet Gynecol. 2012;128:1–11.
15.
Zurück zum Zitat Pennant ME, Mehta R, Moody P, Hackett G, Prentice A, Sharp SJ, et al. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG. 2017;124:404–11. CrossRef Pennant ME, Mehta R, Moody P, Hackett G, Prentice A, Sharp SJ, et al. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG. 2017;124:404–11. CrossRef
17.
Zurück zum Zitat Walsh C, Holschneider C, Hoang Y. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol. 2005;106:693–9. CrossRef Walsh C, Holschneider C, Hoang Y. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol. 2005;106:693–9. CrossRef
18.
Zurück zum Zitat Morice P, Fourchotte V, Sideris L. A need for laparoscopic evaluation of patients with endometrial carcinoma selected for conservative treatment. Gynecol Oncol. 2005;96:245–8. CrossRef Morice P, Fourchotte V, Sideris L. A need for laparoscopic evaluation of patients with endometrial carcinoma selected for conservative treatment. Gynecol Oncol. 2005;96:245–8. CrossRef
19.
Zurück zum Zitat Zarbo G, Caruso G, Caruso S, Mangano U, Zarbo R. Endometrial cancer: preoperative evaluation of myometrial infiltration magnetic resonance imaging versus transvaginal ultrasonography. Eur J Gynaecol Oncol. 2000;21(1):95–7. PMID: 10726632. PubMed Zarbo G, Caruso G, Caruso S, Mangano U, Zarbo R. Endometrial cancer: preoperative evaluation of myometrial infiltration magnetic resonance imaging versus transvaginal ultrasonography. Eur J Gynaecol Oncol. 2000;21(1):95–7. PMID: 10726632. PubMed
20.
Zurück zum Zitat Nouri K, Reinthaller A. Fertilitätserhalt bei prämenopausalen Frauen mit # Endometriumkarzinom im frühen, niedriggradigen Stadium. Speculum. 2015;33(1):12–6. Nouri K, Reinthaller A. Fertilitätserhalt bei prämenopausalen Frauen mit # Endometriumkarzinom im frühen, niedriggradigen Stadium. Speculum. 2015;33(1):12–6.
21.
Zurück zum Zitat Cosgrove CM, Cohn DE, Hampel H, et al. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. Gynecol Oncol. 2017;146:588–95. CrossRef Cosgrove CM, Cohn DE, Hampel H, et al. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. Gynecol Oncol. 2017;146:588–95. CrossRef
22.
Zurück zum Zitat Cohn DE, Frankel WL, Resnick KE, et al. Improved survival with an intact DNA mismatch repair system in endometrial cancer. Obstet Gynecol. 2006;108:1208–15. CrossRef Cohn DE, Frankel WL, Resnick KE, et al. Improved survival with an intact DNA mismatch repair system in endometrial cancer. Obstet Gynecol. 2006;108:1208–15. CrossRef
23.
Zurück zum Zitat Wei J, Zhang W, Feng L, Gao W. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: a meta-analysis and systematic review. Medicine (Baltimore). 2017;96:e8034. CrossRef Wei J, Zhang W, Feng L, Gao W. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: a meta-analysis and systematic review. Medicine (Baltimore). 2017;96:e8034. CrossRef
24.
Zurück zum Zitat Son J, Carr C, Yao M, et al. Endometrial cancer in young women: prognostic factors and treatment outcomes in women aged ≤40 years. Int J Gynecol Cancer. 2020;30:631–9. CrossRef Son J, Carr C, Yao M, et al. Endometrial cancer in young women: prognostic factors and treatment outcomes in women aged ≤40 years. Int J Gynecol Cancer. 2020;30:631–9. CrossRef
25.
Zurück zum Zitat Harrison RF, He W, Fu S, et al. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer oratypical hyperplasia. Am J Obstet Gynecol. 2019;221:474.e1–11. Harrison RF, He W, Fu S, et al. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer oratypical hyperplasia. Am J Obstet Gynecol. 2019;221:474.e1–11.
26.
Zurück zum Zitat Mazzon I, Corrado G, Masciullo V, et al. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril. 2010;93:1286–9. CrossRef Mazzon I, Corrado G, Masciullo V, et al. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril. 2010;93:1286–9. CrossRef
28.
Zurück zum Zitat Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207:266.e1–266.e12. CrossRef Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207:266.e1–266.e12. CrossRef
30.
Zurück zum Zitat Shih KK, Garg K, Levine DA, et al. Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40 years of age and younger. Gynecol Oncol. 2011;123:88–94. CrossRef Shih KK, Garg K, Levine DA, et al. Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40 years of age and younger. Gynecol Oncol. 2011;123:88–94. CrossRef
Metadaten
Titel
Fertility preservation in women with endometrial cancer
verfasst von
MD Helena Bralo
MD Maria Roethlisberger
MD Assoc. Prof. Kazem Nouri
Publikationsdatum
29.10.2020
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-020-00661-6